Vivos Therapeutics Q2 FY25: Revenue up 25%, Acquires Sleep Center of Nevada

• Vivos Therapeutics acquires The Sleep Center of Nevada, generating revenue & seeing strong demand. • Q2 2025 financial results not specified. • Conference call scheduled for today at 5:00 pm ET. • Vivos specializes in sleep-related breathing disorders treatments. • Company focuses on OSA in adults & children ages 6-17. • Financial results not detailed in the provided article.

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of proprietary treatments for sleep-related breathing disorders, has reported significant progress following its acquisition of The Sleep Center of Nevada (SCN). The acquisition, completed in June 2025, has marked a pivotal shift in the company's strategy from a dentist-focused model to a direct, patient-centric sleep center approach. Vivos Therapeutics is scheduled to host a conference call today at 5:00 pm ET to discuss the second quarter 2025 financial results and operational updates.

The acquisition of SCN, the largest operator of medical sleep centers in Nevada, has generated incremental revenue and strong patient demand for Vivos' differentiated array of highly effective obstructive sleep apnea (OSA) treatments. The company reported approximately $500,000 in diagnostic sleep testing services revenue over just twenty days from the June 10 closing to the end of the quarter. The rapid operational integration and strong patient demand have exceeded management's expectations, suggesting a successful transition to the new model.

Vivos Therapeutics has developed a sleep optimization (SO) team structure to address patient backlogs and facility constraints. The company projects deploying 3.5 SO teams in Las Vegas by year-end 2025, with each team potentially able to process up to 250 patients monthly and targeting contribution margins above 50%. The SO team model positions Vivos Therapeutics for scalable growth and improved profitability as more teams are deployed in additional markets.

To finance the SCN acquisition and ongoing expansion, Vivos Therapeutics raised $11.5 million net through debt and equity, including capital from major investor Seneca Partners. As of June 30, 2025, the company reported $4.4 million in cash and $21.5 million in total liabilities. Management acknowledges the high cost of current debt but expresses confidence in qualifying for conventional bank lending as revenue predictability improves.

The second quarter of 2025 financial results, including revenue and operating expenses, are expected to be discussed during the scheduled conference call. Management aims to reach cash flow breakeven in the fourth quarter of 2025, driven by the deployment of additional SO teams and expanded facility capacity. The company plans to have 3.5 SO teams operating at SCN by year-end 2025, expand into Michigan under a new management collaboration, and pursue further sleep center acquisitions and affiliations.

Investors and financial professionals are encouraged to attend the conference call to gain a deeper understanding of Vivos Therapeutics' financial performance and strategic initiatives.

References:
[1] https://www.nasdaq.com/articles/vivos-therapeutics-unveils-new-model
[2] https://www.biospace.com/press-releases/vivos-therapeutics-reports-second-quarter-2025-financial-results-and-provides-operational-update